Royalty Pharma (RPRX) said Friday it has agreed to acquire its external manager, RP Management for about $1.1 billion, including 24.5 million in shares that will vest over five to nine years, about $100 million in cash, and the assumption of $380 million of debt.
The transaction is meant to simplify its corporate structure and reduce costs, generating anticipated cash savings of more than $100 million in 2026 and $175 million in 2030, the company said.
The transaction is expected to close in H1, the company said.
The company said it also approved a new $3 billion share repurchase program, including $2 billion in shares it expects to buy back in 2025.
The repurchase program replaces the unused $465 million of the company's $1.0 billion share repurchase program launched in 2023, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。